Atogepant for migraine

Drugs Today (Barc). 2022 Aug;58(8):399-405. doi: 10.1358/dot.2022.58.8.3408815.

Abstract

Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a key role in migraine. Medications targeting CGRP are being used as migraine preventive and abortive treatments.

Keywords: Analgesic drugs; Antimigraine drugs; Atogepant; Calcitonin gene-related peptide (CGRP) receptor antagonists; Gepants; Migraine with aura; Migraine without aura.

MeSH terms

  • Analgesics / therapeutic use
  • Calcitonin Gene-Related Peptide
  • Calcitonin Gene-Related Peptide Receptor Antagonists* / therapeutic use
  • Humans
  • Migraine Disorders* / drug therapy
  • Piperidines
  • Pyridines
  • Pyrroles
  • Spiro Compounds

Substances

  • Analgesics
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Piperidines
  • Pyridines
  • Pyrroles
  • Spiro Compounds
  • atogepant
  • Calcitonin Gene-Related Peptide